ANI Pharmaceuticals, Inc.: insider trading
882 trades by 35 directors, officers and 10% owners since 2010, from their SEC Form 4 and 5 filings.
Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$14.0 M
49 sales by 11 insiders
Bought, 3 months
$0
0 purchases
Sold, 3 months
$2.4 M
12 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (35)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| Nikhil LalwaniPRESIDENT & CEO, Director | 328,289 | — | $5.8 M | |
| Meredith CookSR. VP, GENERAL COUNSEL & SEC. | 72,924 | — | $455 K | |
| Stephen P. CareySVP & CFO | 166,143 | — | $2.2 M | |
| Jeanne ThomaDirector | 26,762 | — | $72 K | |
| Henry O. GosebruchDirector | 6,662 | — | — | |
| Ori GutwergSVP, GENERICS | 75,534 | — | $621 K | |
| Thomas HaugheyDirector | 38,878 | — | $162 K | |
| Antonio R. PeraDirector | 27,017 | — | — | |
| Matthew J. LeonardDirector | 11,221 | — | — | |
| Renee P. TannenbaumDirector | 29,514 | — | $146 K | |
| Patrick D. WalshDirector | 38,432 | — | $1.6 M | |
| Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | 38,271 | — | $394 K | |
| Christopher MutzHEAD OF RARE DISEASE | 91,309 | — | $1.6 M | |
| Krista DavisSVP, CHIEF HR OFFICER | 51,946 | — | $919 K | |
| Chad GassertSVP - CORP. DEV. & STRATEGY | 74,916 | — | — | |
| Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | 101,056 | — | — | |
| James G. MarkenSVP OPS & PROD DEV | 117,829 | — | — | |
| Meridian Venture Partners II LP10% owner | 1.82 M | — | — | |
| David NashDirector | 38,561 | — | — | |
| Meridian Venture Partners II GP, L.P.10% owner | 2.02 M | — | — | |
| Robert E. Brown Jr.Director | 49,021 | — | — | |
| Robert W. SchrepferSVP - NEW BUS DEV & SPEC SALES | 87,477 | — | — | |
| Arthur PrzybylPresident and CEO, Director | 190,309 | — | — | |
| Thomas A. PennDirector | 14,301 | — | — | |
| Tracy MarshbanksDirector | 11,110 | — | — | |
| Fred HolubowDirector | 14,811 | — | — | |
| Daniel RaynorDirector | 11,110 | — | — | |
| Charlotte C. ArnoldVice President and CFO | 54,298 | — | — | |
| Peter A. LankauDirector | 2,500 | — | — | |
| Ross J. ManganoDirector | 26,914 | — | — | |
| Robert J. JamnickVP, Quality & Product Develop. | 48,118 | — | — | |
| Edward C. Rosenow IIIDirector | 20,540 | — | — | |
| Louis W. SullivanDirector | 47,898 | — | — | |
| Philip B. DonenbergSr. VP of Finance, CFO & Secy | 44,322 | — | — | |
| Stephen M. SimesVice Chairman, President & CEO, Director | — | — | — |
Trades#
The newest 300 trades.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell10b5-1 plan | -4,082 | $71.16 | $290 K | 328,289 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell10b5-1 plan | -1,318 | $71.40 | $94 K | 332,371 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $70.80 | $35 K | 72,924 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell10b5-1 plan | -2,850 | $72.87 | $208 K | 166,143 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell10b5-1 plan | -5,400 | $71.89 | $388 K | 333,689 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $73.59 | $37 K | 73,424 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell10b5-1 plan | -2,850 | $73.00 | $208 K | 168,993 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell10b5-1 plan | -5,400 | $71.00 | $383 K | 339,089 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $70.79 | $35 K | 73,924 | Form 4 |
| filed | Jeanne ThomaDirector | Sell10b5-1 plan | -1,000 | $71.53 | $72 K | 26,762 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell10b5-1 plan | -2,850 | $72.80 | $207 K | 171,843 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell10b5-1 plan | -5,400 | $74.30 | $401 K | 344,489 | Form 4 |
| filed | Henry O. GosebruchDirector | Grant or award | +6,662 | — | — | 6,662 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $75.48 | $38 K | 74,424 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Sell | -3,162 | $77.00 | $243 K | 75,534 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell10b5-1 plan | -2,850 | $81.36 | $232 K | 174,693 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax | -2,466 | $79.20 | $195 K | 74,924 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $81.84 | $41 K | 77,390 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Option exercise10b5-1 plan | +3,313 | $49.51 | $164 K | 180,856 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell10b5-1 plan | -3,313 | $86.00 | $285 K | 177,543 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell10b5-1 plan | -2,850 | $84.12 | $240 K | 177,543 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $82.03 | $41 K | 77,890 | Form 4 |
| filed | Thomas HaugheyDirector | Sell10b5-1 plan | -2,000 | $80.88 | $162 K | 38,878 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Option exercise10b5-1 plan | +3,312 | $49.51 | $164 K | 183,705 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell10b5-1 plan | -3,312 | $80.00 | $265 K | 180,393 | Form 4 |
| filed | Thomas HaugheyDirector | Grant or award10b5-1 plan | +4,357 | — | — | 40,878 | Form 4 |
| filed | Matthew J. LeonardDirector | Grant or award | +4,357 | — | — | 11,221 | Form 4 |
| filed | Renee P. TannenbaumDirector | Grant or award | +4,357 | — | — | 29,514 | Form 4 |
| filed | Jeanne ThomaDirector | Grant or award | +4,357 | — | — | 27,762 | Form 4 |
| filed | Antonio R. PeraDirector | Grant or award | +4,357 | — | — | 27,017 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $78.16 | $39 K | 78,390 | Form 4 |
| filed | Patrick D. WalshDirector | Sell | -10,000 | $80.63 | $806 K | 38,432 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Sell | -459 | $79.21 | $36 K | 38,271 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Sell | -2,772 | $79.50 | $220 K | 78,696 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell | -55,000 | $77.57 | $4.3 M | 349,889 | Form 4 |
| filed | Patrick D. WalshDirector | Sell | -3,973 | $80.75 | $321 K | 48,432 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $77.95 | $39 K | 78,890 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $72.62 | $36 K | 79,390 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell10b5-1 plan | -3,162 | $71.64 | $227 K | 91,309 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Sell | -4,772 | $74.91 | $357 K | 38,730 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -5,087 | $74.13 | $377 K | 51,946 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell10b5-1 plan | -3,602 | $74.18 | $267 K | 94,471 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -5,150 | $74.04 | $381 K | 180,393 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -3,314 | $74.04 | $245 K | 81,468 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -17,060 | $74.04 | $1.3 M | 404,889 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax10b5-1 plan | -3,314 | $74.04 | $245 K | 98,073 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell10b5-1 plan | -2,121 | $74.22 | $157 K | 101,387 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -1,485 | $75.00 | $111 K | 57,033 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Option exercise | +3,312 | $49.51 | $164 K | 192,855 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell | -3,312 | $75.42 | $250 K | 189,543 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell | -4,000 | $75.56 | $302 K | 185,543 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Sell | -2,060 | $76.50 | $158 K | 84,782 | Form 4 |
| filed | Patrick D. WalshDirector | Sell | -6,000 | $74.23 | $445 K | 52,405 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell10b5-1 plan | -417 | $74.00 | $31 K | 103,508 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -2,773 | $73.90 | $205 K | 189,543 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Shares withheld for tax | -2,221 | $73.90 | $164 K | 74,916 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax | -1,555 | $73.90 | $115 K | 79,890 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -1,555 | $73.90 | $115 K | 58,518 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Shares withheld for tax | -628 | $73.90 | $46 K | 43,502 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -2,221 | $73.90 | $164 K | 86,842 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -12,217 | $73.90 | $903 K | 421,949 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -2,221 | $73.90 | $164 K | 103,925 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Grant or award | +22,233 | $77.15 | $1.7 M | 192,316 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Grant or award | +11,116 | $77.15 | $858 K | 101,056 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Grant or award | +11,116 | $77.15 | $858 K | 77,137 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Grant or award | +13,895 | $77.15 | $1.1 M | 81,445 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Grant or award | +10,810 | $77.15 | $834 K | 60,073 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Grant or award | +6,021 | $77.15 | $465 K | 44,130 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Grant or award | +12,969 | $77.15 | $1.0 M | 89,063 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Grant or award | +75,592 | $77.15 | $5.8 M | 434,166 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Grant or award | +21,306 | $77.15 | $1.6 M | 106,146 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell10b5-1 plan | -5,323 | $78.02 | $415 K | 84,840 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -1,730 | $77.99 | $135 K | 49,263 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -2,084 | $77.53 | $162 K | 50,993 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -2,448 | $77.36 | $189 K | 170,083 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Shares withheld for tax | -1,717 | $77.36 | $133 K | 66,021 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -10,298 | $77.36 | $797 K | 358,574 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -1,290 | $77.36 | $100 K | 53,077 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -1,888 | $77.36 | $146 K | 76,094 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Shares withheld for tax | -485 | $77.36 | $38 K | 38,109 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax10b5-1 plan | -2,403 | $77.36 | $186 K | 90,163 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax10b5-1 plan | -1,779 | $77.36 | $138 K | 67,550 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $76.80 | $38 K | 69,329 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -2,829 | $76.70 | $217 K | 172,531 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax10b5-1 plan | -3,173 | $76.70 | $243 K | 99,598 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Shares withheld for tax | -1,608 | $76.70 | $123 K | 67,738 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -11,688 | $76.70 | $896 K | 368,872 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -1,180 | $76.70 | $91 K | 54,367 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax10b5-1 plan | -1,534 | $76.70 | $118 K | 69,829 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -1,775 | $76.70 | $136 K | 77,982 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Shares withheld for tax | -566 | $76.70 | $43 K | 38,594 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell10b5-1 plan | -7,032 | $76.55 | $538 K | 92,566 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -4,267 | $76.25 | $325 K | 79,757 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Shares withheld for tax | -1,762 | $76.25 | $134 K | 39,160 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -4,546 | $76.25 | $347 K | 102,771 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Shares withheld for tax | -2,898 | $76.25 | $221 K | 89,940 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -30,659 | $76.25 | $2.3 M | 380,560 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax | -3,011 | $76.25 | $230 K | 71,363 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Shares withheld for tax | -4,269 | $76.25 | $326 K | 69,346 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -5,503 | $76.25 | $420 K | 175,360 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -3,017 | $76.25 | $230 K | 55,547 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -500 | $84.33 | $42 K | 74,374 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -1,622 | $82.40 | $134 K | 58,564 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $82.32 | $33 K | 74,874 | Form 4 |
| filed | Renee P. TannenbaumDirector | Sell | -1,800 | $81.15 | $146 K | 25,157 | Form 4 |
| filed | Patrick D. WalshDirector | Sell | -8,643 | $86.88 | $751 K | 61,405 | Form 4 |
| filed | Patrick D. WalshDirector | Gift | -3,000 | — | — | 58,405 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $87.27 | $35 K | 75,274 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Sellindirect | -94 | $88.00 | $8 K | 158,490 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Sellindirect | -14,642 | $89.07 | $1.3 M | 158,584 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $90.09 | $36 K | 75,674 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -1,000 | $98.04 | $98 K | 60,186 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $98.42 | $39 K | 76,074 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -1,710 | $97.71 | $167 K | 61,186 | Form 4 |
| filed | Antonio R. PeraDirector | Sell | -7,292 | $94.94 | $692 K | 22,660 | Form 4 |
| filed | Matthew J. LeonardDirector | Sell | -2,528 | $90.62 | $229 K | 6,864 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell | -1,763 | $91.10 | $161 K | 62,896 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sellindirect | -52,988 | $90.44 | $4.8 M | 431,920 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sellindirect | -47,012 | $90.27 | $4.2 M | 484,908 | Form 4 |
| filed | Antonio R. PeraDirector | Sell | -5,421 | $89.73 | $486 K | 29,952 | Form 4 |
| filed | Jeanne ThomaDirector | Sell | -6,865 | $89.76 | $616 K | 38,080 | Form 4 |
| filed | Jeanne ThomaDirector | Sell | -14,675 | $88.87 | $1.3 M | 23,405 | Form 4 |
| filed | Matthew J. LeonardDirector | Sell | -6,937 | $88.17 | $612 K | 9,392 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Sellindirect | -20,000 | $86.97 | $1.7 M | 173,226 | Form 4 |
| filed | Patrick D. WalshDirector | Sell | -9,000 | $89.05 | $801 K | 70,048 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sellindirect | -52,990 | $87.15 | $4.6 M | 531,920 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sellindirect | -47,010 | $89.48 | $4.2 M | 584,910 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $88.87 | $36 K | 76,474 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Sell | -5,873 | $86.53 | $508 K | 84,024 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Sell | -4,975 | $85.71 | $426 K | 40,794 | Form 4 |
| filed | Thomas HaugheyDirector | Sell | -19,341 | $85.93 | $1.7 M | 36,521 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell | -56,960 | $85.93 | $4.9 M | 411,219 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Option exercise | +50,000 | $46.49 | $2.3 M | 230,863 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell | -50,000 | $86.07 | $4.3 M | 180,863 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax | -2,071 | $66.30 | $137 K | 76,874 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $64.88 | $26 K | 78,945 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $61.37 | $25 K | 79,345 | Form 4 |
| filed | Antonio R. PeraDirector | Grant or award | +4,336 | — | — | 35,373 | Form 4 |
| filed | Renee P. TannenbaumDirector | Grant or award | +4,336 | — | — | 26,957 | Form 4 |
| filed | Jeanne ThomaDirector | Grant or award | +4,336 | — | — | 44,945 | Form 4 |
| filed | Matthew J. LeonardDirector | Grant or award | +4,336 | — | — | 16,329 | Form 4 |
| filed | Patrick D. WalshDirector | Grant or award | +4,336 | — | — | 79,048 | Form 4 |
| filed | Thomas HaugheyDirector | Grant or award | +4,336 | — | — | 55,862 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Sell | -881 | $60.07 | $53 K | 89,897 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell | -4,000 | $60.45 | $242 K | 107,317 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $62.20 | $25 K | 79,745 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -700 | $76.83 | $54 K | 631,920 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $68.96 | $28 K | 80,145 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -6,210 | $64.26 | $399 K | 180,863 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -17,455 | $64.26 | $1.1 M | 468,179 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -1,866 | $65.00 | $121 K | 64,659 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $63.33 | $25 K | 80,545 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -3,314 | $60.62 | $201 K | 90,778 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -5,150 | $60.62 | $312 K | 187,073 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -2,874 | $60.62 | $174 K | 111,317 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -17,060 | $60.62 | $1.0 M | 485,634 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -1,000 | $60.86 | $61 K | 66,525 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Option exercise | +300 | $31.49 | $9 K | 99,476 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Sell | -300 | $60.03 | $18 K | 99,176 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Sell | -5,084 | $60.00 | $305 K | 94,092 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -12,216 | $61.89 | $756 K | 502,694 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Shares withheld for tax | -627 | $61.89 | $39 K | 45,465 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -1,861 | $61.89 | $115 K | 192,223 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax | -1,099 | $61.89 | $68 K | 80,945 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -1,275 | $61.89 | $79 K | 114,191 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -1,570 | $61.89 | $97 K | 99,176 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -1,099 | $61.89 | $68 K | 67,525 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -1,000 | $60.20 | $60 K | 68,624 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -1,184 | $58.92 | $70 K | 115,466 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -1,167 | $58.92 | $69 K | 100,746 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -1,473 | $58.92 | $87 K | 116,650 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -1,426 | $58.92 | $84 K | 101,913 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Shares withheld for tax | -582 | $58.92 | $34 K | 46,092 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -7,799 | $58.92 | $460 K | 514,910 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -1,196 | $58.92 | $70 K | 69,624 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -1,730 | $58.92 | $102 K | 194,084 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax10b5-1 plan | -1,434 | $58.92 | $84 K | 82,044 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $59.54 | $24 K | 83,478 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Grant or award | +13,057 | — | — | 62,116 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Grant or award10b5-1 plan | +16,974 | — | — | 72,562 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Grant or award | +14,362 | — | — | 83,014 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Grant or award | +7,834 | — | — | 41,452 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Grant or award | +91,399 | — | — | 461,777 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Grant or award | +14,362 | — | — | 64,041 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Grant or award | +24,808 | — | — | 179,276 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Grant or award | +15,668 | — | — | 92,895 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Grant or award | +24,808 | — | — | 101,585 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Grant or award | +60,932 | — | — | 522,709 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Grant or award | +8,704 | — | — | 70,820 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Grant or award | +9,574 | — | — | 92,588 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Grant or award | +16,538 | — | — | 195,814 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Grant or award | +16,538 | — | — | 118,123 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Grant or award | +10,444 | — | — | 103,339 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Grant or award | +9,574 | — | — | 73,615 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Grant or award | +5,222 | — | — | 46,674 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Grant or award10b5-1 plan | +11,316 | — | — | 83,878 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -400 | $53.92 | $22 K | 55,588 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell | -7,500 | $55.79 | $418 K | 154,468 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $56.24 | $14 K | 55,988 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Sell10b5-1 plan | -1,000 | $60.00 | $60 K | 49,059 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Option exercise | +30,000 | $29.00 | $870 K | 403,859 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell | -30,000 | $57.95 | $1.7 M | 373,859 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell | -3,481 | $58.30 | $203 K | 370,378 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell | -6,500 | $57.70 | $375 K | 76,777 | Form 4 |
| filed | Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS | Shares withheld for tax | -867 | $56.58 | $49 K | 33,169 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $61.36 | $15 K | 56,238 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $57.19 | $14 K | 56,488 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $56.82 | $14 K | 56,738 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -1,486 | $56.15 | $83 K | 50,059 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -3,646 | $60.51 | $221 K | 373,859 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $59.62 | $15 K | 56,988 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -2,743 | $62.00 | $170 K | 632,620 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax | -1,743 | $61.35 | $107 K | 57,238 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -14,257 | $63.16 | $900 K | 635,363 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -22,000 | $64.27 | $1.4 M | 649,620 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -11,000 | $63.38 | $697 K | 671,620 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $64.91 | $16 K | 58,981 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Sell10b5-1 plan · indirect | -20,000 | $63.44 | $1.3 M | 193,226 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -20,000 | $58.90 | $1.2 M | 682,620 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -11,447 | $59.86 | $685 K | 702,620 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -10,607 | $60.76 | $644 K | 714,067 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -7,946 | $61.41 | $488 K | 724,674 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $63.80 | $16 K | 59,231 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Option exercise | +7,250 | $49.51 | $359 K | 123,616 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Option exercise | +5,300 | $57.06 | $302 K | 128,916 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Shares withheld for tax | -11,087 | $67.70 | $751 K | 117,829 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Sell | -2,985 | $67.00 | $200 K | 77,227 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell | -5,000 | $63.58 | $318 K | 161,968 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Sell10b5-1 plan · indirect | -20,000 | $64.41 | $1.3 M | 213,226 | Form 4 |
| filed | Jeanne ThomaDirector | Grant or award | +4,410 | — | — | 40,609 | Form 4 |
| filed | Matthew J. LeonardDirector | Grant or award | +4,410 | — | — | 11,993 | Form 4 |
| filed | Renee P. TannenbaumDirector | Grant or award | +4,410 | — | — | 22,621 | Form 4 |
| filed | Antonio R. PeraDirector | Grant or award | +4,410 | — | — | 31,037 | Form 4 |
| filed | Patrick D. WalshDirector | Grant or award | +4,410 | — | — | 74,712 | Form 4 |
| filed | Thomas HaugheyDirector | Grant or award | +4,410 | — | — | 51,526 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell | -2,000 | $61.61 | $123 K | 83,277 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -12,855 | $61.81 | $795 K | 732,620 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -5,836 | $62.09 | $362 K | 745,475 | Form 4 |
| filed | Renee P. TannenbaumDirector | Sell | -2,000 | $63.87 | $128 K | 18,211 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -16,459 | $63.84 | $1.1 M | 751,311 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -14,850 | $65.86 | $978 K | 767,770 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell | -16,669 | $66.10 | $1.1 M | 377,505 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $67.69 | $17 K | 59,481 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Sell10b5-1 plan · indirect | -20,000 | $66.62 | $1.3 M | 233,226 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -16,809 | $65.17 | $1.1 M | 782,620 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -10,423 | $64.98 | $677 K | 799,429 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -9,520 | $65.40 | $623 K | 809,852 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -5,834 | $66.20 | $386 K | 819,372 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -7,414 | $66.33 | $492 K | 825,206 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $67.79 | $17 K | 59,731 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -4,534 | $66.96 | $304 K | 166,968 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Shares withheld for tax | -2,799 | $66.96 | $187 K | 116,006 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Sell10b5-1 plan · indirect | -20,000 | $67.25 | $1.3 M | 253,226 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Shares withheld for tax | -3,653 | $69.58 | $254 K | 118,805 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -17,455 | $69.58 | $1.2 M | 394,174 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -6,210 | $69.58 | $432 K | 171,502 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Sell10b5-1 plan | -250 | $66.54 | $17 K | 59,981 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Sell10b5-1 plan · indirect | -20,000 | $65.81 | $1.3 M | 273,226 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Sell | -7,787 | $65.55 | $510 K | 177,712 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -10,000 | $67.17 | $672 K | 832,620 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell | -16,292 | $67.13 | $1.1 M | 411,629 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -4,216 | $66.71 | $281 K | 185,499 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -17,060 | $66.71 | $1.1 M | 427,921 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -2,110 | $66.71 | $141 K | 85,277 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Sell | -24,338 | $66.37 | $1.6 M | 124,492 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -2,494 | $66.71 | $166 K | 80,212 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Shares withheld for tax | -2,034 | $66.71 | $136 K | 122,458 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -15,085 | $66.35 | $1.0 M | 842,620 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Sell | -28,965 | $65.52 | $1.9 M | 444,981 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -14,822 | $65.47 | $970 K | 857,705 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Sell10b5-1 plan · indirect | -10,093 | $65.35 | $660 K | 872,527 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Sell | -5,000 | $66.00 | $330 K | 87,387 | Form 4 |
| filed | Antonio R. PeraDirector | Sell | -7,000 | $65.20 | $456 K | 26,627 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -1,275 | $67.67 | $86 K | 92,387 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -1,570 | $67.67 | $106 K | 82,706 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Shares withheld for tax | -1,635 | $67.67 | $111 K | 49,679 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Shares withheld for tax | -1,173 | $67.67 | $79 K | 51,545 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Shares withheld for tax | -1,122 | $67.67 | $76 K | 68,652 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Shares withheld for tax | -1,914 | $67.67 | $130 K | 189,715 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Shares withheld for tax | -1,058 | $67.67 | $72 K | 148,830 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Shares withheld for tax | -10,014 | $67.67 | $678 K | 473,946 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Shares withheld for tax | -1,173 | $67.67 | $79 K | 60,231 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Shares withheld for tax | -1,261 | $57.55 | $73 K | 93,662 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Shares withheld for tax | -1,244 | $57.55 | $72 K | 84,276 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Grant or award | +13,421 | — | — | 42,368 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Grant or award | +12,079 | — | — | 44,666 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Grant or award | +13,421 | — | — | 60,828 | Form 4 |
| filed | Nikhil LalwaniPRESIDENT & CEO, Director | Grant or award | +80,530 | — | — | 430,274 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Grant or award | +21,474 | — | — | 177,313 | Form 4 |
| filed | James G. MarkenSVP OPS & PROD DEV | Grant or award | +10,066 | — | — | 143,178 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Grant or award | +14,763 | — | — | 75,678 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Grant or award | +18,790 | — | — | 82,397 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Grant or award | +14,763 | — | — | 51,562 | Form 4 |
| filed | Krista DavisSVP, CHIEF HR OFFICER | Grant or award | +8,052 | — | — | 52,718 | Form 4 |
| filed | Chad GassertSVP - CORP. DEV. & STRATEGY | Grant or award | +8,946 | — | — | 51,314 | Form 4 |
| filed | Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS, Director | Grant or award | +8,946 | — | — | 69,774 | Form 4 |
| filed | Stephen P. CareySVP & CFO | Grant or award | +14,316 | — | — | 191,629 | Form 4 |
| filed | Ori GutwergSVP, GENERICS | Grant or award | +9,842 | — | — | 85,520 | Form 4 |
| filed | Meredith CookSR. VP, GENERAL COUNSEL & SEC. | Grant or award | +9,842 | — | — | 61,404 | Form 4 |
| filed | Christopher MutzHEAD OF RARE DISEASE | Grant or award | +12,526 | — | — | 94,923 | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice